WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis

How to Cite

OrthoEvidence. WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis. ACE Report. 2016;5(5):7. Available from: https://myorthoevidene.com/AceReport/Report/8928

Study Type:Randomized Trial

OE Level Evidence:N/A

Journal Level of Evidence:N/A

Effects of abaloparatide on vertebral, nonvertebral, major osteoporotic and clinical fracture incidence in postmenopausal women with osteoporosis: result of the phase 3 ACTIVE trial

Contributing Authors: LA Fitzpatrick P Miller F Cosman D Black E Lau CAF Zerbini BJ Riis C Christiansen G Williams MY Hu G Hattersley

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Access conference website and list of abstracts.

Synopsis

2463 postmenopausal women with osteoporosis were randomized to one of three groups: daily subcutaneous abaloparatide (80ug), daily subcutaneous teriparatide (20ug), or daily subcutaneous placebo. The treatment period was 18 months, and patients were assessed for bone mineral density and incident fracture rate. Abaloparatide treatment was reported to result in a significantly greater increase in bo...